In last trading session, Transmedics Group Inc (NASDAQ:TMDX) saw 1.78 million shares changing hands with its beta currently measuring 2.14. Company’s recent per share price level of $79.42 trading at $4.4 or 5.87% at ring of the bell on the day assigns it a market valuation of $2.67B. That closing price of TMDX’s stock is at a discount of -123.33% from its 52-week high price of $177.37 and is indicating a premium of 30.75% from its 52-week low price of $55.00.
For Transmedics Group Inc (TMDX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.70. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.15 in the current quarter.
Transmedics Group Inc (NASDAQ:TMDX) trade information
Upright in the green during last session for gaining 5.87%, in the last five days TMDX remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $79.42 price level, adding 0.11% to its value on the day. Transmedics Group Inc’s shares saw a change of 27.38% in year-to-date performance and have moved 16.61% in past 5-day. Transmedics Group Inc (NASDAQ:TMDX) showed a performance of 38.85% in past 30-days.
Wall Street analysts have assigned a consensus price target of 109 to the stock, which implies a rise of 27.14% to its current value. Analysts have been projecting 90 as a low price target for the stock while placing it at a high target of 125. It follows that stock’s current price would drop -13.32% in reaching the projected high whereas dropping to the targeted low would mean a loss of -13.32% for stock’s current value.
Transmedics Group Inc (TMDX) estimates and forecasts
This year revenue growth is estimated to rise 77.76% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 109.49M for the same. And 6 analysts are in estimates of company making revenue of 119.4M in the next quarter. Company posted 81.17M and 96.85M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.36% during past 5 years.
Transmedics Group Inc (NASDAQ:TMDX)’s Major holders
FMR LLC is the top institutional holder at TMDX for having 4.49 million shares of worth $676.31 million. And as of 2024-06-30, it was holding 13.7063 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 2.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.0755 of outstanding shares, having a total worth of $398.47 million.
On the other hand, iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 2.16 shares of worth $171.39 million or 6.43% of the total outstanding shares. The later fund manager was in possession of 1.02 shares on Sep 30, 2024 , making its stake of worth around $80.97 million in the company or a holder of 3.04% of company’s stock.
